Drugs / Celery Seed
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06061926 | May 2023 → Jun 2025 overdue | metabolic syndrome X | University of Guadalajara | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Celery Seed | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06061926 ↗ |
| Known as | Apium graveolens L. | “This study aimed to evaluate the effect of celery seed (Apium graveolens L.) administration on the components of MetS, insulin sensitivity, and insulin secretion.” PMID 41599709 ↗ Jan 2026 |
| Route | Oral | “Oral administration.” NCT06061926 ↗ |